Paradigm Biocapital Advisors LP → MBX Biosciences, Inc. MBX

Stake: — Shares: — Class: Common Stock, $0.0001 par value per share

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

6 transactions

6 buys · 0 sales · 0 awards/exercises

Issuer Cluster

6 13D/G filings on this issuer

5 other filings besides this one

Filer Track Record

2 filings by this filer

1 other filing in the data moat

Short Interest · settle 2026-07-31

DTC 8.52

5,188,562 shares short · -10.2% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers

1 holder · $21.47M

Point72 Asset Mgmt

Form 4 Insider Transactions · last 365d

Date	Insider	Role	Type	Shares	Price	Value
2026-06-04	Pescovitz Ora H.	director	Award	12,500	$30.91	$386K
2026-06-04	Heron Patrick J	director, 10%+ owner	Award	12,500	$30.91	$386K
2026-06-04	Stelzer Laurie	director	Award	12,500	$30.91	$386K
2026-06-04	Hoerter Steven L.	director	Award	12,500	$30.91	$386K
2026-06-04	Ryder Steven	director	Award	12,500	$30.91	$386K
2026-06-04	Aynechi Tiba	director	Award	12,500	$30.91	$386K

Other 13D/G Filings on MBX Biosciences, Inc.

Filed	Form	Filer	Stake	Shares
2026-08-10	SCHEDULE 13D/A	Frazier Life Sciences Public Fund, L.P.	—	1,429,573	view →
2026-08-10	SCHEDULE 13D/A	ORBIMED ADVISORS LLC	—	3,074,853	view →
2025-09-30	SCHEDULE	Frazier Life Sciences Public Fund, L.P.	11.70%	5,224,095	view →
2025-09-30	SCHEDULE	ORBIMED ADVISORS LLC	9.00%	4,002,887	view →
2025-09-30	SCHEDULE	Norwest Venture Partners XVI, LP	4.80%	2,140,989	view →

Other Filings by Paradigm Biocapital Advisors LP

Filed	Form	Issuer	Stake	Shares
2026-06-26	SCHEDULE 13G	Viridian Therapeutics, Inc. VRDN	—	—	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →